Clinical Trials Browser

Tamoxifen × 30 days × Clear all

NCT06179303 2026-04-16

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Phase 2 Recruiting

Anatomic Stage III Breast Cancer AJCC v8

NCT04852887 2026-04-15

DEBRA

Phase 3 Recruiting

Breast Neoplasms

NCT01127295 2026-04-14

PHACS

Phase 4 Completed

Breast Neoplasms

NCT01553903 2026-04-14

OXYTAM

Phase 4 Completed

Breast Neoplasms

NCT01612871 2026-04-14

MIRHO

Phase 4 Completed

Breast Neoplasms

NCT00310180 2026-04-13

TAILORx

Phase 3 Active not recruiting

10,273 enrolled 14 charts

Breast Neoplasms

NCT01272037 2026-04-13

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

Phase 3 Active not recruiting

5,018 enrolled 14 charts

Carcinoma, Intraductal, Noninfiltrating

NCT02311933 2026-04-13

Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Phase 2 Active not recruiting

81 enrolled 9 charts

Breast Neoplasms

NCT02630693 2026-04-13

Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

Phase 2 Completed

180 enrolled 14 charts

Breast Neoplasms

NCT05774951 2026-04-13

CAMBRIA-1

Phase 3 Recruiting

Breast Neoplasms

NCT05941520 2026-04-13

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

Phase 2 Recruiting

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT06184750 2026-04-13

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

Phase 2 Recruiting

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT06195306 2026-04-13

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

Phase 2 Recruiting

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT06979596 2026-04-13

OMAHA-015

Phase 2 Recruiting

Neoplasms

NCT06440967 2026-04-06

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy

Phase 3 Active not recruiting

Hot Flashes

NCT04569747 2026-04-02

ADEPT

Phase 2 Active not recruiting

Breast Neoplasms

NCT05161195 2026-04-02

Roll-over Study to Allow Continued Access to Ribociclib

Phase 4 Active not recruiting

Breast Neoplasms

NCT05514054 2026-04-02

EMBER-4

Phase 3 Active not recruiting

Breast Neoplasms

NCT07499999 2026-03-30

BabyTEARS

Phase 2 Not yet recruiting

Breast Neoplasms, Carcinoma, Ductal

NCT06492616 2026-03-27

ELEGANT

Phase 3 Recruiting

Breast Neoplasms, Breast Neoplasms, Male

NCT07287098 2026-03-27

preEMBER

Phase 2 Not yet recruiting

Breast Neoplasms

NCT05659563 2026-03-19

EMPRESS

Phase 2 Completed

92 enrolled 14 charts

Breast Neoplasms

NCT07349069 2026-03-19

A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With High-Risk Early Breast Cancer

Phase 3 Recruiting

Breast Neoplasms